Clinical trials
Refractory Osteosarcoma clinical trials
Below are recruiting refractory osteosarcoma clinical trials, each written for real people, not researchers. We’re tracking 18 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07211737RecruitingPhase 1
C7R-GD2 CAR-T cells for osteosarcoma or neuroblastoma
This trial tests a new treatment using your own immune cells (called C7R-GD2 CAR-T cells) that are trained to find and kill cancer cells. It's for children and young adults with osteosarcoma or neuroblastoma that has not gotten better with standard treatments.
Houston, TexasAges 1–24 - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Palo Alto, CaliforniaAges 1–30 - NCT05019703RecruitingPhase 2
Atezolizumab plus cabozantinib for teen osteosarcoma
This trial studies a combination of two medicines—atezolizumab and cabozantinib—for teenagers and young adults with osteosarcoma that has come back or spread. It aims to slow or shrink the cancer and help control disease that can’t be fully removed with surgery.
Boston, MassachusettsAges 12 years+ - NCT05400603RecruitingPhase 1
Immunotherapy trial for relapsed neuroblastoma or osteosarcoma
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
Atlanta, GeorgiaAges 1 year+ - NCT07144254RecruitingPhase 1
Tegavivint and gemcitabine for relapsed osteosarcoma
This trial tests a new drug called tegavivint combined with the chemotherapy drug gemcitabine for people whose osteosarcoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink or control the cancer.
Atlanta, GeorgiaAges 1–30 - NCT07227571RecruitingPhase 1
CAR T cells for advanced osteosarcoma
This trial tests whether specially engineered immune cells (called CAR T cells) can attack and kill osteosarcoma tumors that have not responded to standard treatments. It may be an option for children and adults whose cancer has returned or is not controlled by chemotherapy.
Seattle, WashingtonAges 1–75 - NCT04616560RecruitingPhase 2
New drug for recurrent Wilms tumor, osteosarcoma, and DSRCT
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
Birmingham, AlabamaAges 12–39 - NCT07774533RecruitingEarly Phase 1
Imaging osteosarcoma with a new PET tracer
This trial tests a new PET imaging tracer that may help see osteosarcoma tumors more clearly. It is for people whose osteosarcoma has not improved or has returned after standard treatment.
Beijing, Beijing MunicipalityAges 10–80 - NCT07479732RecruitingPhase 1/Phase 2
Apatinib with chemo for advanced osteosarcoma
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
BeijingAges 12–65 - NCT07357519RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced osteosarcoma
This trial tests a new targeted radiation treatment (177Lu-TARGETed Osteosarcoma Therapy) for people with advanced osteosarcoma that has not responded to or has come back after prior chemotherapy. The goal is to see if this treatment can help shrink or control the cancer.
Los Angeles, CaliforniaAges 12 years+ - NCT05830123RecruitingPhase 2
Test drug HS-20093 for osteosarcoma after earlier treatment
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
BeijingAges 18 years+ - NCT05588648RecruitingPhase 1/Phase 2
Testing vactosertib for osteosarcoma that keeps coming back
This Phase 1/2 study tests how safe and how well vactosertib works for adolescents and adults with osteosarcoma that has returned, stopped responding, or is getting worse despite prior treatment. You may be able to join if you meet age, cancer, recovery-from-prior-therapy, and health-test requirements.
Cleveland, OhioAges 12 years+ - NCT07725380RecruitingPhase 1/Phase 2
Two drugs for relapsed sarcoma or osteosarcoma
This trial studies a new combination of two drugs, domatinostat and sirolimus, for people with sarcoma or osteosarcoma that hasn't improved after standard treatments. The goal is to see if this combination can help shrink or slow the cancer.
Tampa, FloridaAges 12–40 - NCT05227326RecruitingPhase 1
A new drug for solid cancers that did not respond to usual care
This early-stage (Phase 1) trial tests AOH1996 in adults with solid tumors that have stopped responding to standard treatments. It’s meant to find a safe dose and see if the drug can help, especially in cancers with limited options.
Scottsdale, ArizonaAges 18 years+ - NCT06709495RecruitingPhase 1/Phase 2
PEEL-224 with chemo for teens and young adults with sarcoma
This trial tests a new drug called PEEL-224 combined with two chemotherapy drugs (vincristine and temozolomide) for people ages 12 to 49 with sarcoma that has come back or hasn't responded to standard treatments. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 12–49 - NCT06541262RecruitingPhase 1/Phase 2
Silmitasertib plus chemo for relapsed solid tumors
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Birmingham, AlabamaAges Up to 30 years - NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+
Hear when a new Refractory Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Refractory Osteosarcoma trials by city
Studies with a site in or near these metro areas.
Refractory Osteosarcoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for refractory osteosarcoma?
- Yes. Clin2 currently lists 18 recruiting refractory osteosarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory osteosarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory osteosarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.